1st Topical JAK Inhibitor in Line for Japan Approval in January

Japan could see approval of its first topical JAK inhibitor as early as January 2020 as Japan Tobacco’s delgocitinib sailed through a key health ministry advisory committee on October 25 for the treatment of atopic dermatitis. Delgocitinib, a JAK inhibitor...read more